MSF said the deals with generic companies meant it was now able to provide a 12-week course of treatment for around $120, against $1,400 to $1,800 available through Gilead and BMS access programs for poorer nations.

As part of a novel, once-daily, single-tablet HIV treatment, bictegravir could offer new option for people living with HIV in low- and middle-income countries Geneva, 4 October 2017 — The Medicines Patent Pool (MPP) today announced a licence with Gilead Sciences for bictegravir (BIC), now under ...

The World Heath Organization and UNAIDS have announced approval of a revolutionary pricing agreement that will facilitate access to the first affordable and all-purpose single-pill HIV regimen including Dolutegravir (DTG) for the public sector in low and middle-income countries. Its price will be around 75 ...

On September 22, a workshop for patient communities on accessibility of innovation in HIV treatment in Ukraine was held in Kyiv. During the workshop, influential international organizations – the EATG and the East Europe and Central Asia Union of People Living with HIV (ECUO) – ...

A breakthrough pricing agreement has been announced which will accelerate the availability of the first affordable, generic, single-pill HIV treatment regimen containing dolutegravir (DTG) to public sector purchasers in low- and middle-income countries (LMICs) at around US$75 per person, per year. The agreement is expected to ...

In early September, Poland became the platform for the first presentation and discussion of the "Concept of the East Europe and Central Asia Union of People Living with HIV on access to treatment in the EECA region". The key aspect of the Concept is the ...

The AIDS response in Africa has come a long way and the continent is seeing results in many areas, including the dramatic reduction in the number of babies being born with HIV and an equally dramatic increase in access to HIV treatment. Nevertheless, inequalities in ...

High drug pricing for interferon-free direct acting antiviral regimens (up to US$93 000 per 12 week course) has limited broad implementation in the vast majority of settings, with restrictions based on liver disease stage generally introduced to reduce budget impact. Other restrictions, including those based on ...

After several years of lobbying work and pressure from patient organisations, the European Parliament has now published a report on the EU’s options for improving access to medicines. This useful snapshot from the European Public Health Alliance describes the report. The report is non-binding though ...

Growing up in eastern Ukraine, Svitlana Moroz said she was a typically reckless teenager who believed she’d live forever. She shared needles with friends to inject opium, had unprotected sex with a guy her own age, and five months after hooking up with him, learned she ...

Last June, a Perspective piece in the New England Journal of Medicine noted the critical place that the World Health Organization’s list of Essential Medicines had assumed in global health policy and responses — donors, governments and insurers were all more likely to invest in ...

Following individuals through the cascade of care, from HIV diagnosis to treatment and undetectable viral load, rather than taking snapshots of performance, has led researchers on a major South African study to pinpoint linkage to care after testing HIV positive as the biggest weakness of ...

European Medicines Agency grants accelerated assessment, validates Marketing Authorization Application for AbbVie’s investigational regimen of glecaprevir/pibrentasvir (G/P) for the treatment of chronic hepatitis C in all major genotypes (GT1-6) – If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority ...

Experts discuss the devastating effects of prohibition and their reasons for reform The war on drugs has had devastating effects on human rights and public health worldwide, argue experts in The BMJ. In November, the journal argued that prohibition laws have failed and called on doctors to ...

A new WHO report provides insight into how countries in the WHO European Region can improve access and reduce medicine prices through strategic and well-planned procurement processes. It also addresses collaboration within and across countries to improve availability of affordable medicines for patients in the ...

Research carried out by Mount Sinai Medical Center, New York, found that non-adherence was the strongest risk factor for treatment failure in people taking sofosbuvir/ledipasvir (Harvoni). The main reasons cited for non-adherence were failing to take medication as prescribed and hospitalisation. The findings were presented at ...